Dergiler / Uluslararası Hematoloji-Onkoloji Dergisi / 2017 / Cilt: 27 - Sayı: 1

Association Between PON1 L55M Polymorphism and PON1 Enzyme Activity in Patients with Leukemia

Lösemi Hastalarında PON1 L55M Polimorfizmi ile PON1 Enzim Aktivitesi Arasındaki İlişk

Sayfa
21–28
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Furthermore, older age may be a risk factor for developing leukemia.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Paraoxonase 1 (PON1) is an important antioxidant enzyme which has a role in preventing the effects of systemic oxidative stress.
📊
Temel Bulgular & Veri:The purpose of our study was to investigate the possible association between PON1 L55M polymorphism and leukemia development and to determine the relationship between PON1 genotypes and PON1 enzyme activities.
💡
Sonuç & Katkı:Furthermore, older age may be a risk factor for developing leukemia.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Paraoxonase 1 (PON1) is an important antioxidant enzyme which has a role in preventing the effects of systemic oxidative stress. The purpose of our study was to investigate the possible association between PON1 L55M polymorphism and leukemia development and to determine the relationship between PON1 genotypes and PON1 enzyme activities. Genotypes of 102 cases and 112 healthy controls were determined by PCR-RFLP. PON1 enzyme activity was determined according to Eckerson’s method. The ratio of MM genotype belonging to PON1 L55M polymorphism in control group was 6.3% and was 7.8% in patients with leukemia (p= 0.39). PON1 enzyme activity was 118.8 ± 115.1 U/mL in control group, while decreased to 75.6 ± 64.4 U/mL in patients with leukemia (p= 0.004). PON1 enzyme activities of the individuals with MM genotypes belonging to PON1 L55M polymorphism was 57.43 ± 21.61 U/mL in control group and decreased to 39.18 ± 45.61 U/mL in leukemic patients. Our results suggest that, PON1 L55M polymorphism genotype ratios do not affect leukemia development. However, reduced PON1 enzyme activity and also the combination of PON1 L55M polymorphism with reduced PON1 enzyme activity are associated with the increased risk of leukemia. Furthermore, older age may be a risk factor for developing leukemia.

Abstract

Paraoksonaz 1 (PON1), sistemik oksidatif stresin etkilerini önlemede rol oynayan önemli bir antioksidan enzimdir. Çalışmamızın amacı, PON1 L55M polimorfizmi ve lösemi gelişimi arasındaki olası ilişkiyi araştırmak ve PON1 genotipleri ile PON1 enzim aktiviteleri arasındaki ilişkiyi saptamaktır. Lösemi tanısı almış 102 hasta birey ve 112 sağlıklı kontrol grubunun genotipleri PCR-RFLP yöntemi ile belirlendi. PON1 enzim aktivitesi Eckerson yöntemi ile ölçüldü. PON1 L55M polimorfizmine ait MM genotip oranları kontrol grubunda %6.3 iken lösemili hastalarda % 7.8 idi (p= 0.39). PON1 enzim aktivitesi kontrol grubunda 118.8 ± 115.1 U/mL iken lösemili hastalarda düşük olarak saptandı (75.6 ± 64.4 U/mL, p= 0.004). PON1 L55M polimorfizmine ait MM genotipli bireylerin PON1 enzim aktivitesi kon-trol grubunda 57.43 ± 21.61 U/mL iken lösemili hastalarda düşük olarak saptandı (39.18 ± 45.61 U/mL). Bizim bulgularımız PON1 L55M polimorfizmi genotip oranlarının lösemi gelişimini etkilemediğini göstermektedir. Bununla birlikte, düşük PON1 enzim aktivitesi tek başına ve PON1 L55M polimorfizmi ile birlikte lösemi riski artışı ile ilişkilidir. Ayrıca ileri yaş lösemiye yakalanma olasılığını yükseltir.

🔖

Bu Makaleye Atıf Yap

ERAS, N., TOMBAK, A., YALIN, S., BERKÖZ, M., KUL, S., AKBAŞ, E. (2017). Association Between PON1 L55M Polymorphism and PON1 Enzyme Activity in Patients with Leukemia. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 27 - Sayı: 1, 21–28. https://ajindex.com/articles/322791

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. van Ginkel G, Sevanian A. Lipid peroxidation-induced mem-brane structural alterations. Methods Enzymol 233: 273-288 1994.
  2. Al-Gayyar MM, Eissa LA, Rabie AM, El-Gayar AM. Measure-ments of oxidative stress status and antioxidant activity in chronic leukaemia patients. J Pharm Pharmacol 59: 409-417, 2007.
  3. Hu P, Ma Y, Zhang L, Ma S. PON1 L55M polymorphism might contribute to the risk of cancer. Panminerva Med 59:107-113 2017
  4. Chen L, Lu W, Fang L, et al. Association between L55M poly-morphism in Paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies. Onco Targets Ther 4:1151-1158, 2016.
  5. Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct 22: 163- 168, 2004. de AguiarGonçalves BA, Vasconcelos GM, Thuler LC, et al. NQO1 rs1800566 (C609T), PON1 rs662 (Q192R), and PON1 rs854560 (L55M) polymorphisms segregate the risk of child-hood acute leukemias according to age range distribution. Cancer Causes Control 23: 1811-1819, 2012.
  6. Stevens VL, Rodriguez C, Talbot JT, et al. Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nu-trition Cohort. Prostate 68: 1336-1340, 2008.
  7. Hussein YM, Gharib AF, Etewa RL, ElSawy WH. Association of L55M and Q192R polymorphisms in paraoxonase1 (PON1) gene with breast cancer risk and their clinical significance. Mol Cell Biochem 351: 117-123, 2011.
  8. Naidu R, Har YC, Taib NA. Genetic Polymorphisms of paraox-onase 1 (PON1) Gene: association between L55 M or Q192R with breast cancer risk and clinico-pathological parameters. Pathol Oncol Res 16: 533-540, 2010.
  9. Antognelli C, Del Buono C, Ludovini V, et al. CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 9: 115, 2009.
  10. Yildirim S, Akar S, Kuyucu M, et al. Paraoxonase 1 gene poly-morphisms, paraoxonase/arylesterase activities and oxidized low-density lipoprotein levels in patients with migraine. Cell Biochem Funct 29: 549-554, 2011.
  11. Arpaci A, Görmüs U, Dalan B, et al. Investigation of PON1 192 and PON1 55 polymorphisms in ovarian cancer patients in Turkish population. In Vivo 23: 421-424, 2009
  12. Altuner D, Ates I, Suzen SH, et al. The relationship of PON1 QR 192 and LM 55 polymorphisms with serum paraoxonase activities of Turkish diabetic patients. Toxicol Ind Health 27: 873-878, 2011.
  13. Eckerson HW, Wyte CM, La Du BN. The huma